AMO Pharma announces results of Phase 2 proof-of-concept study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1 – Patients showed significant improvements in cognitive function, levels of fatigue and ability to perform daily tasks – Treatment shown to be safe and well tolerated AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical […]
